Literature DB >> 19101686

Vascular dysfunction in glycogen storage disease type I.

Angelina V Bernier1, Catherine E Correia, Michael J Haller, Douglas W Theriaque, Jonathan J Shuster, David A Weinstein.   

Abstract

OBJECTIVE: To determine cardiovascular disease risk in a larger cohort of patients with glycogen storage disease (GSD) I through the use of noninvasive measures of arterial function and anatomy. STUDY
DESIGN: Carotid intima media thickness (IMT), radial artery tonometry, and brachial artery reactivity were performed in 28 patients with GSD I (13F/15M, mean age 23 years) and 23 control subjects (19F/4M, mean age 23 years).
RESULTS: The primary outcome measure, mean left distal IMT was greater in the GSD cohort (0.500+/-0.055 mm) than in the control group (0.457+/-0.039 mm) (P= .002, adjusted for age, sex, and body mass index). Mean augmentation index measured by radial artery tonometry was higher in the GSD cohort (16.4%+/-14.0%) than in the control group (2.4%+/-8.7%) (P< .001). No significant difference was observed between mean brachial artery reactivity in the GSD cohort (6.3%+/-4.9% change) versus control subjects (6.6%+/-5.1% change) (P= .46).
CONCLUSIONS: GSD I is associated with arterial dysfunction evident by increased IMT and augmentation index. Patients with GSD I may be at increased risk for cardiovascular disease.

Entities:  

Mesh:

Year:  2008        PMID: 19101686      PMCID: PMC3607442          DOI: 10.1016/j.jpeds.2008.10.048

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  20 in total

Review 1.  The molecular background of glycogen metabolism disorders.

Authors:  O N Elpeleg
Journal:  J Pediatr Endocrinol Metab       Date:  1999 May-Jun       Impact factor: 1.634

Review 2.  Glycogen storage diseases.

Authors:  Joseph I Wolfsdorf; David A Weinstein
Journal:  Rev Endocr Metab Disord       Date:  2003-03       Impact factor: 6.514

Review 3.  Vasoactive substances: nitric oxide and endothelial dysfunction in atherosclerosis.

Authors:  Guilia Russo; Jane A Leopold; Joseph Loscalzo
Journal:  Vascul Pharmacol       Date:  2002-05       Impact factor: 5.773

Review 4.  Noninvasive tests of vascular function and structure: why and how to perform them.

Authors:  R Fathi; T H Marwick
Journal:  Am Heart J       Date:  2001-05       Impact factor: 4.749

5.  Association between increased arterial-wall thickness and impairment in ABCA1-driven cholesterol efflux: an observational study.

Authors:  Marjel J van Dam; Eric de Groot; Susanne M Clee; G Kees Hovingh; Roosje Roelants; Angie Brooks-Wilson; Aeilko H Zwinderman; Andries J Smit; August H M Smelt; Albert K Groen; Michael R Hayden; John J P Kastelein
Journal:  Lancet       Date:  2002-01-05       Impact factor: 79.321

Review 6.  Cellular cholesterol efflux.

Authors:  C J Fielding; P E Fielding
Journal:  Biochim Biophys Acta       Date:  2001-10-31

Review 7.  Statin-fibrate combination therapy.

Authors:  A Shek; M J Ferrill
Journal:  Ann Pharmacother       Date:  2001 Jul-Aug       Impact factor: 3.154

8.  Is glycogen storage disease 1a associated with atherosclerosis?

Authors:  Froukje L Ubels; Jan Peter Rake; Joris P J Slaets; G Peter A Smit; Andries J Smit
Journal:  Eur J Pediatr       Date:  2002-07-02       Impact factor: 3.183

9.  Plasma antioxidants in pediatric patients with glycogen storage disease, diabetes mellitus, and hypercholesterolemia.

Authors:  Birgit Wittenstein; Marcus Klein; Barbara Finckh; Kurt Ullrich; Alfried Kohlschütter
Journal:  Free Radic Biol Med       Date:  2002-07-01       Impact factor: 7.376

10.  Increased levels of hemostatic proteins are independent of inflammation in glycogen storage disease type Ia.

Authors:  Anne Marfaing-Koka; Martine Wolf; Catherine Boyer-Neumann; Dominique Meyer; Michel Odievre; Philippe Labrune
Journal:  J Pediatr Gastroenterol Nutr       Date:  2003-11       Impact factor: 2.839

View more
  6 in total

Review 1.  Dietary dilemmas in the management of glycogen storage disease type I.

Authors:  Kaustuv Bhattacharya
Journal:  J Inherit Metab Dis       Date:  2011-04-14       Impact factor: 4.982

Review 2.  iPS cell modeling of cardiometabolic diseases.

Authors:  Kenta Nakamura; Ken-ichi Hirano; Sean M Wu
Journal:  J Cardiovasc Transl Res       Date:  2012-10-16       Impact factor: 4.132

3.  Glycogen Storage Disease type 1a - a secondary cause for hyperlipidemia: report of five cases.

Authors:  Patrícia Margarida Serra Carvalho; Nuno José Marques Mendes Silva; Patrícia Glória Dinis Dias; João Filipe Cordeiro Porto; Lèlita Conceição Santos; José Manuel Nascimento Costa
Journal:  J Diabetes Metab Disord       Date:  2013-06-06

4.  Glycogen Storage Disease Type I (Von Gierke disease): Report of Two Cases with Severe Dyslipidemia.

Authors:  Julia Maria Avelino Ballavenuto; Jéssica D Ório Dantas de Oliveira; Renato Jorge Alves
Journal:  Arq Bras Cardiol       Date:  2020-05-18       Impact factor: 2.000

Review 5.  Glucose-6-phosphatase deficiency.

Authors:  Roseline Froissart; Monique Piraud; Alix Mollet Boudjemline; Christine Vianey-Saban; François Petit; Aurélie Hubert-Buron; Pascale Trioche Eberschweiler; Vincent Gajdos; Philippe Labrune
Journal:  Orphanet J Rare Dis       Date:  2011-05-20       Impact factor: 4.123

Review 6.  Lipids in hepatic glycogen storage diseases: pathophysiology, monitoring of dietary management and future directions.

Authors:  Terry G J Derks; Margreet van Rijn
Journal:  J Inherit Metab Dis       Date:  2015-01-30       Impact factor: 4.982

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.